2015 American Society of Clinical Oncology Annual Meeting*

Download All
May 29-June 2, 2015; Chicago, Illinois
David F. McDermott, MD, and Daniel P. Petrylak, MD, review data from key genitourinary cancer presentations from the 2015 clinical oncology meeting in Chicago.
David F. McDermott, MD
Daniel P. Petrylak, MD

Genitourinary Cancers

This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.

Released: June 4, 2015

Updated results from a phase Ib dose-expansion study in UBC suggest that the anti–PD-L1 antibody atezolizumab yields greater efficacy in patients with higher expression of PD-L1 on immune cells.

Released: June 5, 2015

Updated data from the urothelial cohort that demonstrate favorable and durable activity of pembrolizumab.

Released: June 5, 2015

Randomized phase II trial results of a Hsp27 inhibitor suggest potential benefit among patients with poor prognostic features at baseline.

Released: June 4, 2015

Results of this phase II study indicate promising response rates and survival in both tubulin inhibitor–naive and tubulin inhibitor–exposed patients.

Released: June 4, 2015

Results of the first randomized, individualized therapy study in metastatic bladder cancer.

Released: June 4, 2015

Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.

Released: June 4, 2015

Results of the largest controlled trial in metastatic nonclear-cell RCC show different efficacy among the VEGF-TKI and mTOR inhibitor in specific subgroups.

Released: June 4, 2015

Results of a dose amendment to the phase III ASSURE trial; impact on safety and clinical outcome discussed.

Released: June 4, 2015

Mutations in MTOR, TSC1, and TSC2, but not PTEN or PIK3CA, were associated with complete responses to mTOR inhibitors in patients with metastatic RCC.

Released: June 4, 2015

Interesting results of a large randomized, multiarm, multistage trial that indicate a potential change in standard of care.

Released: June 5, 2015

Biopsy study identified an important new histologic subtype, which when combined with SCNC, represents the largest group of AR therapy–resistant patients.

Released: June 5, 2015

A retrospective exploratory analysis of the phase III SYNERGY trial shows that adding custirsen to docetaxel/prednisone selectively improves survival in treatment-naive patients with mCRPC and a poor prognosis.

Released: June 5, 2015

David F. McDermott, MD, and Daniel P. Petrylak, MD, provide their analysis of key genitourinary cancer presentations from the 2015 clinical oncology meeting in Chicago.

David F. McDermott, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 13, 2015 Expired: No longer available for credit

In this downloadable slideset, David F. McDermott, MD, and Daniel P. Petrylak, MD, review key studies presented at the 2015 American Society of Clinical Oncology Annual Meeting relevant to the management of patients with prostate, kidney, or bladder cancers.

Released: August 20, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue